9 trials tracked for metastasis: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 24 citations.
Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical investigations into metastatic disease have evaluated the efficacy of Dasatinib. Data indicate varying rates of objective response and disease control across different study cohorts, with reported disease control rates ranging from 6.67% to 16.13% 7.
In studies evaluating Dasatinib, the percentage of participants achieving a complete or partial response was recorded at 8.7% in one cohort compared to 0.0% in another 6. Additionally, specific cohorts showed progression-free survival (PFS) rates at various intervals (weeks 9, 17, and 25) ranging from 7% to 50% 7.
The use of NKTR-102 has been evaluated in a Phase 3 trial for this condition 2.
AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
